INVEGA SUSTENNA® is approved for the treatment of schizoaffective disorder

Safety and Tolerability for Schizoaffective Disorder

Most common adverse reactions1

In the 5 pivotal trials for INVEGA SUSTENNA® in patients with schizophrenia, the most common adverse reactions (incidence ≥5% and occurring at least twice as often as placebo) were1:

  • Injection-site reactions
  • Somnolence/sedation
  • Dizziness
  • Akathisia
  • Extrapyramidal disorder

No occurrences of adverse events reached this threshold in the 15-month, double-blind, placebo-controlled phase in patients with schizoaffective disorder.1

The following adverse reactions occurred more frequently (a ≥2% difference vs placebo) in the long-term study in patients with schizoaffective disorder1:

  • Weight increased
  • Nasopharyngitis
  • Headache
  • Hyperprolactinemia
  • Pyrexia

Indicated for the treatment of schizoaffective disorder.

The full constellation of symptoms and the relevant diagnostic criteria should be consulted and are available in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5®, or current version), where applicable.

Additional safety information1
Data presented are for the double-blind phase of the schizoaffective study only.

Reference: 1. INVEGA SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2018.

Content area 1.2